AD/PD Therapeutic Target Comparison Matrix

📖 Wiki Page

therapeutic767 wordssynced 2026-04-02

AD/PD Therapeutic Target Comparison Matrix

Overview

flowchart TD AD_PD_Therapeutic_Target_Compa["AD/PD Therapeutic Target Comparison Matrix"] AD_PD_Therapeutic_Target_Compa["table"] AD_PD_Therapeutic_Target_Compa -->|"related to"| AD_PD_Therapeutic_Target_Compa style AD_PD_Therapeutic_Target_Compa fill:#81c784,stroke:#333,color:#000 AD_PD_Therapeutic_Target_Compa["class"] AD_PD_Therapeutic_Target_Compa -->|"related to"| AD_PD_Therapeutic_Target_Compa style AD_PD_Therapeutic_Target_Compa fill:#81c784,stroke:#333,color:#000 AD_PD_Therapeutic_Target_Compa["infobox"] AD_PD_Therapeutic_Target_Compa -->|"related to"| AD_PD_Therapeutic_Target_Compa style AD_PD_Therapeutic_Target_Compa fill:#81c784,stroke:#333,color:#000 style AD_PD_Therapeutic_Target_Compa fill:#4fc3f7,stroke:#333,color:#000

...

AD/PD Therapeutic Target Comparison Matrix

Overview

Mermaid diagram (expand to render)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">AD/PD Therapeutic Target Comparison Matrix</th>
</tr>
<tr>
<td class="label">Target</td>
<td>AD Approach</td>
</tr>
<tr>
<td class="label">Amyloid-beta</td>
<td>Anti-Abeta monoclonal antibodies (lecanemab, donanemab)</td>
</tr>
<tr>
<td class="label">Tau protein</td>
<td>Anti-tau immunotherapies, kinase inhibitors</td>
</tr>
<tr>
<td class="label">alpha-Synuclein</td>
<td>N/A</td>
</tr>
<tr>
<td class="label">TDP-43</td>
<td>N/A</td>
</tr>
<tr>
<td class="label">Target</td>
<td>AD Drug Class</td>
</tr>
<tr>
<td class="label">Dopamine</td>
<td>Not applicable</td>
</tr>
<tr>
<td class="label">Dopamine receptors</td>
<td>Not applicable</td>
</tr>
<tr>
<td class="label">Cholinergic</td>
<td>Cholinesterase inhibitors</td>
</tr>
<tr>
<td class="label">Glutamate</td>
<td>NMDA antagonist</td>
</tr>
<tr>
<td class="label">Adenosine</td>
<td>Not applicable</td>
</tr>
<tr>
<td class="label">Serotonin</td>
<td>SSRIs</td>
</tr>
<tr>
<td class="label">Gene Target</td>
<td>AD Approach</td>
</tr>
<tr>
<td class="label">APP</td>
<td>ASO targeting APP</td>
</tr>
<tr>
<td class="label">SNCA</td>
<td>N/A</td>
</tr>
<tr>
<td class="label">GBA</td>
<td>N/A</td>
</tr>
<tr>
<td class="label">LRRK2</td>
<td>N/A</td>
</tr>
<tr>
<td class="label">BDNF</td>
<td>AAV-BDNF</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>AD Targets</td>
</tr>
<tr>
<td class="label">Neuroinflammation</td>
<td>Anti-inflammatory drugs, GLP-1 agonists</td>
</tr>
<tr>
<td class="label">Oxidative stress</td>
<td>Antioxidants</td>
</tr>
<tr>
<td class="label">Mitochondrial dysfunction</td>
<td>GLP-1, mitochondria-targeted</td>
</tr>
<tr>
<td class="label">Protein homeostasis</td>
<td>Proteostasis modulators</td>
</tr>
<tr>
<td class="label">Metal homeostasis</td>
<td>Metal chelators</td>
</tr>
<tr>
<td class="label">Target Class</td>
<td>AD Candidates</td>
</tr>
<tr>
<td class="label">GLP-1 receptor</td>
<td>Semaglutide, liraglutide</td>
</tr>
<tr>
<td class="label">Sigma-1 receptor</td>
<td>Anavex 2-73</td>
</tr>
<tr>
<td class="label">CB1/CB2 cannabis</td>
<td>Nabilone</td>
</tr>
<tr>
<td class="label">TRPV1 capsaicin</td>
<td>Not in AD</td>
</tr>
<tr>
<td class="label">5-HT6 receptor</td>
<td>Idalopirdine</td>
</tr>
<tr>
<td class="label">Priority</td>
<td>AD Targets</td>
</tr>
<tr>
<td class="label">P0</td>
<td>Abeta, Tau</td>
</tr>
<tr>
<td class="label">P1</td>
<td>Neuroinflammation</td>
</tr>
<tr>
<td class="label">P2</td>
<td>Synaptic function</td>
</tr>
<tr>
<td class="label">P3</td>
<td>Metabolic support</td>
</tr>
</table>

This page provides a comprehensive comparison of therapeutic targets across Alzheimer's Disease (AD) and Parkinson's Disease (PD), highlighting common mechanisms, disease-specific approaches, and clinical development status.

Target Categories

1. Protein Aggregation Targets

2. Neurotransmitter-Based Therapies

3. Gene Therapy Approaches

4. Immunotherapy Approaches

Alzheimer's Disease

Anti-amyloid antibodies: Lecanemab, donanemab, aducanumab
Anti-tau vaccines: ACI-35, BVRL-001
Mechanism: Clear Aβ plaques, reduce tau tangles

Parkinson's Disease

Anti-α-synuclein antibodies: Cinpanemab, prasinezumab
Vaccines: PD01A, PD03A
Mechanism: Clear Lewy bodies, prevent propagation

5. Neuroprotection and Disease Modification

6. Receptor and Channel Targets

Clinical Trial Comparison

Alzheimer's Disease Pipeline (2024)

Phase 3: 15+ candidates
Phase 2: 50+ candidates
Disease modification: 8 candidates
Symptomatic: 7 candidates
Biomarker-driven: Most programs

Parkinson's Disease Pipeline (2024)

Phase 3: 10+ candidates
Phase 2: 40+ candidates
Disease modification: 6 candidates
Gene therapy: 5 programs
Cell therapy: 3 programs

Shared Therapeutic Strategies

Disease-Modifying Approaches

Protein clearance: Immunotherapies targeting misfolded proteins

Neuroinflammation: Microglial modulation, NLRP3 inhibitors

Synaptic protection: BDNF signaling, synaptic vesicle modulators

Metabolic support: Mitochondrial function, bioenergetics

Symptomatic Relief

Cognitive enhancement: Cholinesterase inhibitors, glutamatergic modulators

Motor symptoms: Dopaminergic, adenosine antagonism

Non-motor symptoms: Sleep, mood, autonomic

Target Prioritization Matrix

Cross-Disease Therapeutic Opportunities

High Potential

GLP-1 agonists: Active in both AD and PD trials

TREM2 modulators: Microglial targeting in AD, potential in PD

Autophagy enhancers: Protein clearance in both

NLRP3 inhibitors: Neuroinflammation in both

Medium Potential

Antioxidants: Mitochondrial protection

Metal chelators: Metal dysregulation

Cell therapy: Stem cell approaches

Low Potential (Disease-Specific)

APP-targeted: AD only

Dopaminergic: PD only

Tau vaccines: AD only

References

[Cummings et al., Alzheimer's disease drug development pipeline (2024)](https://doi.org/10.1002/alz.13858)

[Pagano et al., Parkinson's disease drug pipeline (2024)](https://doi.org/10.1038/s41573-024-00936-1)

[Knight et al., Gene therapy for neurodegenerative diseases (2024)](https://doi.org/10.1038/s41582-024-00856-1)

[Therapeutic Targets Overview](/therapeutics/therapeutic-targets)
[Immunotherapy Comparison](/therapeutics/immunotherapy-comparison)
[Antibody Comparison Matrix](/therapeutics/antibody-comparison-matrix)
[Combination Therapy Matrix](/therapeutics/ad-combination-therapy-matrix)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Glial Glycocalyx Remodeling Therapy](/hypothesis/h-c35493aa) — 0.58 · Target: HSPG2
[TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — 0.55 · Target: TREM2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF
[Smartphone-Detected Motor Variability Correction](/hypothesis/h-072b2f5d) — 0.63 · Target: DRD2/SNCA
[TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — 0.58 · Target: TREM2

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄

📖 View canonical wiki page →

AD/PD Therapeutic Target Comparison Matrix

AD/PD Therapeutic Target Comparison Matrix

Overview

AD/PD Therapeutic Target Comparison Matrix

Overview

Target Categories

1. Protein Aggregation Targets

2. Neurotransmitter-Based Therapies

3. Gene Therapy Approaches

4. Immunotherapy Approaches

Alzheimer's Disease

Parkinson's Disease

5. Neuroprotection and Disease Modification

6. Receptor and Channel Targets

Clinical Trial Comparison

Alzheimer's Disease Pipeline (2024)

Parkinson's Disease Pipeline (2024)

Shared Therapeutic Strategies

Disease-Modifying Approaches

Symptomatic Relief

Target Prioritization Matrix

Cross-Disease Therapeutic Opportunities

High Potential

Medium Potential

Low Potential (Disease-Specific)

References

Related Pages

Related Hypotheses